CD96-binding agent used in treatment of disease in patient, where disease is cancer or infectious disease, and treatment is monotherapy, is capable of stimulating activation and/or proliferation of T cells upon binding to CD96

Renart-Depontieu, Florence, Takami, Sachiko, Margall-Ducos, Germain, Beltraminelli, Nicola, Garrone, Pierre, Rogel, Anne, Al-Shamkhani, Aymen and Preville, Xavier (Inventors) (2019) CD96-binding agent used in treatment of disease in patient, where disease is cancer or infectious disease, and treatment is monotherapy, is capable of stimulating activation and/or proliferation of T cells upon binding to CD96. WO2019030377-A1.

Abstract

NOVELTY - CD96-binding agent is capable of stimulating activation and/or proliferation of T cells upon binding to CD96.

USE - CD96-binding agent used in treatment of a disease in a patient, where the disease is a cancer or an infectious disease, and treatment is a monotherapy, or combination therapy, and used in combination with a co-stimulating agent or an immune checkpoint inhibitor in particular a T cell co-stimulating agent or an immune checkpoint inhibitor, for stimulation of the activation and/or proliferation of T cells upon binding to CD96, and used as an adjuvant in a prophylactic or therapeutic vaccine (all claimed).

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following:

(1) an isolated nucleic acid, which encodes the amino acid sequence of the CD96-binding agent;

(2) an isolated cell that produces the CD96-binding agent; and

(3) a pharmaceutical composition, which comprises the CD96-binding agent and a pharmaceutical acceptable excipient or carrier.

This record has no associated files available for download.

Contributors

Inventor: Aymen Al-Shamkhani

Download statistics